SCHEMBL390796

SCHEMBL390796

O=S(=O)(Cl)C1CCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL68569 0.93
SCHEMBL5075588 0.90 CA1 (0.38)
SCHEMBL15856951 0.90 CA1 (0.38)
SCHEMBL159029 0.90 CA1 (0.38)
SCHEMBL14463171 0.90 CA1 (0.38)
SCHEMBL14641415 0.90 CA1 (0.38)
SCHEMBL18811684 0.90 CA1 (0.38)
SCHEMBL5075567 0.90 CA1 (0.38)
SCHEMBL22022206 0.90 CA1 (0.38)
SCHEMBL14548867 0.90 CA1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122080012-A Thienopyrimidine derivative, preparation method, application and pharmaceutical composition thereof 2026-05-26 CN disclosed
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-23 US disclosed
EP-4263518-B1 NEW QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-01 EP disclosed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
US-12570615-B2 Quinazolinone derivatives HOFFMANN-LA ROCHE INC. 2026-03-10 US disclosed
EP-4703353-A1 PESTICIDALLY-ACTIVE 2,2-DIHALOCYCLOPROPYL COMPOUNDS Syngenta Crop Protection AG (CH) 2026-03-04 EP disclosed
US-20250270180-A1 MEK INHIBITORS AND THERAPEUTIC USES THEREOF IMMUNEERING CORPORATION 2025-08-28 US disclosed
US-12351566-B2 MEK inhibitors and therapeutic uses thereof IMMUNEERING CORPORATION (US) 2025-07-08 US disclosed
EP-4563579-A1 MACROCYCLIC EGFR INHIBITOR, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF Abbisko Therapeutics Co., Ltd. (CN) 2025-06-04 EP disclosed
WO-2025096858-A1 COMPOUNDS FOR THE DEGRADATION OF MUTANT BRAF C4 THERAPEUTICS, INC. (US) 2025-05-08 WO disclosed
US-7220881-B2 Process for production of acid anhydride TOKUYAMA CORPORATION (JP) 2007-05-22 US disclosed
WO-2007014011-A2 N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK ARDEA BIOSCIENCES, INC. (US) 2007-02-01 WO disclosed
EP-1230224-B1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES BASILEA PHARMACEUTICA AG (CH) 2004-12-29 EP disclosed
US-20040242929-A1 Process for production of acid anhydride TOKUYAMA CORPORATION (JP) 2004-12-02 US disclosed
US-6821980-B1 Substituted 5-benzyl-2,4-diaminopyrimidines BASILEA PHARMACEUTICA AG (CH) 2004-11-23 US disclosed
EP-1413572-A1 PROCESS FOR PRODUCING ACID ANHYDRIDE Tokuyama Corporation (JP) 2004-04-28 EP disclosed
US-6716843-B2 INHIBITOR OF DIPEPTIDYL-PEPTIDASE IV LES LABORATOIRES SERVIER (FR) 2004-04-06 US disclosed
US-20030087950-A1 New alpha-amino acid sulphonyl compounds LES LABORATOIRES SERVIER (FR) 2003-05-08 US disclosed
EP-1230224-A1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES F. HOFFMANN-LA ROCHE AG (CH) 2002-08-14 EP disclosed
WO-2001032633-A1 SUBSTITUTED 5-BENZYL-2,4-DIAMINOPYRIMIDINES BASILEA PHARMACEUTICA AG (CH) 2001-05-10 WO disclosed